drugset / Trial / NCT00485823

Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia

NCT00485823

Phase 4 Completed 48 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to develop the weight management program, which is combined with healthy diet, proper physical exercise, and behavior modification, related to patient's quality of life. The patients groups are in routine practice with 5-20 mg olanzapine. The study results may be utilized for patients who have gained weight on olanzapine and also other antipsychotic drugs.

Timeline

Start
2002-12
Primary completion
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Background Olanzapine Small molecule

Indications